12:00 AM
 | 
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

XP21279: Preliminary Phase II data

Preliminary data from 28 evaluable advanced PD patients with motor fluctuations in a double-blind, crossover, U.S. Phase II trial showed that thrice-daily XP21279 plus carbidopa non-significantly reduced mean daily "off" time in which patients experienced symptoms of their PD, the primary endpoint, from baseline to the end of the 2-week, double-blind maintenance treatment periods vs. Sinemet levodopa/carbidopa. Specifically, XP21279 plus carbidopa reduced mean daily "off" time by 2.9 hours vs. 2.6...

Read the full 331 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >